{
  "abstract": "Background\n\nThis is a phase II subprotocol of the National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice (MATCH) precision oncology platform trial evaluating selpercatinib, a RET inhibitor, in children and young adults aged 1-21 years with relapsed or refractory solid tumors with RET alterations.Methods\n\nSelpercatinib was given at 90 mg/m2/dose (maximum dose 160 mg/dose) orally twice daily for 28-day cycles until progression or intolerable toxicity. The primary aim was to determine the objective response rate, and secondary objectives included assessing the tolerability of selpercatinib and estimating the progression-free survival.Results\n\nTwo patients with papillary thyroid carcinomas harboring CCD6C-RET fusions matched to the subprotocol. One patient was deemed ineligible as they had not yet experienced tumor recurrence. The other patient enrolled and received selpercatinib at 90 mg/m2/dose, completing all 26 cycles of protocol therapy and achieving a partial response confirmed by central imaging review. There were no dose-limiting toxicities, and the patient experienced only grade 1 adverse events attributable to selpercatinib.Conclusion\n\nThere was a low match and accrual rate on this MATCH subprotocol, resulting in early termination of the study. The basis for low accrual was likely multifactorial, including the overall rarity of this genetic alteration across pediatric tumor types and accelerated FDA approval of selpercatinib in children ≥12 years old prior to the opening of this subprotocol.Clinical trial registration number\n\nClinicalTrials.gov (NCT04320888).Irb approved\n\nInitial September 14, 2020.",
  "abstract_shown": true,
  "affiliations": [
    "C.S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor, MI 48109, United States.",
    "Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH 43205, United States.",
    "Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States.",
    "University of Texas MD Anderson Cancer Center, Houston, TX, United States.",
    "Center for Biomedical Informatics and Information Technology, NCI, NIH, Bethesda, MD, United States.",
    "Mayo Clinic, Rochester, MN, United States.",
    "Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.",
    "Children's Oncology Group Statistical Center, Monrovia, CA, United States.",
    "Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX, United States.",
    "Ann and Robert H. Lurie Children's Hospital, Chicago, IL, United States.",
    "St. Jude Children's Research Hospital, Memphis, TN, United States.",
    "Seattle Children's Hospital, University of Washington, Seattle, WA, United States.",
    "Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, United States.",
    "Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, United States.",
    "Dana-Farber Cancer Institute, Boston, MA, United States."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 21,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Andrea T Franson",
      "orcid": "0000-0002-5361-7683"
    },
    {
      "affs": [
        1
      ],
      "name": "Samara L Potter",
      "orcid": "0000-0001-7122-953X"
    },
    {
      "affs": [
        2
      ],
      "name": "P Mickey Williams"
    },
    {
      "affs": [
        3
      ],
      "name": "Sinchita Roy-Chowdhuri",
      "orcid": "0000-0002-9447-7701"
    },
    {
      "affs": [
        4
      ],
      "name": "David R Patton",
      "orcid": "0000-0003-3855-0166"
    },
    {
      "affs": [
        4
      ],
      "name": "Brent D Coffey",
      "orcid": "0009-0009-2047-5699"
    },
    {
      "affs": [
        5
      ],
      "name": "Joel M Reid",
      "orcid": "0000-0003-2872-3123"
    },
    {
      "affs": [
        6
      ],
      "name": "Jin Piao",
      "orcid": "0000-0003-0516-6280"
    },
    {
      "affs": [
        7
      ],
      "name": "Lauren Saguilig"
    },
    {
      "affs": [
        6
      ],
      "name": "Todd A Alonzo",
      "orcid": "0000-0002-6772-6581"
    },
    {
      "affs": [
        8
      ],
      "name": "Stacey L Berg"
    },
    {
      "affs": [
        9
      ],
      "name": "Nilsa C Ramirez",
      "orcid": "0000-0002-9945-9449"
    },
    {
      "affs": [
        10
      ],
      "name": "Elizabeth Fox",
      "orcid": "0000-0002-9998-5326"
    },
    {
      "affs": [
        10
      ],
      "name": "Brenda J Weigel",
      "orcid": "0000-0003-1080-1402"
    },
    {
      "affs": [
        11
      ],
      "name": "Douglas S Hawkins",
      "orcid": "0000-0003-3602-1375"
    },
    {
      "affs": [
        12
      ],
      "name": "Margaret M Mooney",
      "orcid": "0000-0002-6998-8331"
    },
    {
      "affs": [
        12
      ],
      "name": "Naoko Takebe",
      "orcid": "0000-0002-5790-4954"
    },
    {
      "affs": [
        13
      ],
      "name": "James V Tricoli"
    },
    {
      "affs": [
        14
      ],
      "name": "Katherine A Janeway"
    },
    {
      "affs": [
        12
      ],
      "name": "Nita L Seibel",
      "orcid": "0000-0001-6259-7955"
    },
    {
      "affs": [
        8
      ],
      "name": "Donald Williams Parsons",
      "orcid": "0000-0002-8775-3501"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/6y698d9d33a9y.bib",
  "cited_by": 0,
  "doi": "10.1093/oncolo/oyag382",
  "fulltext_url": "https://europepmc.org/articles/PMC13681659",
  "id": "6y698d9d33a9y",
  "issns": [
    "1083-7159",
    "1549-490X"
  ],
  "landing_url": "https://europepmc.org/article/MED/42867148",
  "language": "eng",
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2712|Thyroid Cancer Diagnosis and Treatment"
    ]
  ],
  "openalex": "W7221675584",
  "pdf_url": "https://europepmc.org/articles/PMC13681659?pdf=render",
  "pmcid": "PMC13681659",
  "pmid": "42867148",
  "published": "2026-10-01",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/6y698d9d33a9y.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:00Z",
      "native_id": "MED:42867148",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42867148"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2712|Thyroid Cancer Diagnosis and Treatment",
      "subfield": "endocrinology-metabolism"
    }
  ],
  "title": "Phase II study of selpercatinib in children and young adults with RET-altered tumors: arm N of the NCI-COG Pediatric MATCH trial (APEC1621N).",
  "title_text": "Phase II study of selpercatinib in children and young adults with RET-altered tumors: arm N of the NCI-COG Pediatric MATCH trial (APEC1621N).",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:19:00Z",
  "url": "https://research.draconitic.com/paper/6y698d9d33a9y",
  "venue": "The oncologist",
  "versions": []
}